Clinical trials for Pancreas cancer

154 currently recruiting clinical trials

Looking for clinical trials?

Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:

Create your account
Copy-paste your latest medical report
Our AI-based assistant does the rest for you

Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:

Create your account

Early Access Kidney cancer Pancreas cancer

Accès précoce post-AMM - WELIREG (Belzutifan)

Clear cell carcinoma Neuroendocrine tumor Localized Von Hippel-Lindau syndrome (VHL)

1 recruiting site

Merck Sharp & Dohme LLC

Phase 3 Colon cancer Rectal cancer Anal cancer Pancreas cancer Liver and bile duct cancer Stomach and esophageal cancer Small intestine and appendix cancer #NCT07087054 #2024-519875-24-00

[CAREFNDR] Étude d'efficacité portant sur un schéma posologique quotidien de PALTUSOTINE par voie orale dans le traitement du syndrome carcinoïde

Ileum cancer Neuroendocrine tumor None

6 recruiting sites

Crinetics Pharmaceuticals Inc.

Phase 3 Pancreas cancer Stomach and esophageal cancer #NCT06784752 #2024-518325-15-00

[NETTER-3] Étude visant à évaluer l'efficacité et l'innocuité du [177Lu]Lu-DOTA-TATE chez les patients atteints de TNE-GEP avancé de grade 1 et de grade 2

Stomach Neuroendocrine tumor Locally Advanced Metastatic None Systemic Treatment-Naive SSTR Positive

5 recruiting sites

Novartis

Phase 3 Pancreas cancer Stomach and esophageal cancer #NCT05477576 #2023-509334-19-00

[ACTION-1] Étude de RYZ101 comparé au traitement standard chez des patients atteints de tumeur neuroendocrine entéro-gastro-pancréatique bien différencié SSTR+ inopérable ayant progressé après un traitement par 177Lu-SSA

Stomach Neuroendocrine tumor Locally Advanced Metastatic 1 Somatostatin analogs SSTR Positive

Systemic Treatment-Naive

2 recruiting sites

RayzeBio, Inc

Phase 3 Lung cancer Colon cancer Rectal cancer Pancreas cancer Sarcoma and GIST #NCT06332274 #2023-503316-33-00

[UMBRELLA] TISLELIZUMAB chez les patients atteints de cancer avec maladie résiduelle moléculaire

NSCLC (Non-Small Cell Lung Cancer) Soft tissue sarcoma Localized Locally Advanced None Surgery Chemotherapy Surgery Chemotherapy

EGFR Immunotherapy Immunotherapy

4 recruiting sites

Gustave Roussy, Campus du cancer, Grand Paris

Phase 3 Pancreas cancer #NCT04167007 #2024-511904-18-00

[GEMFOX] Étude sur le FOLFOX vs GEMCITABINE chez les patients atteints d'un cancer du pancréas métastatique non éligibles au traitement par FOLFIRINOX

Adenocarcinoma Metastatic None Systemic Treatment-Naive

7 recruiting sites

Assistance Publique - Hôpitaux de Paris

Phase 3 Pancreas cancer #NCT03721744

[STEMLESS] Étude du GB201 en association avec du PACLITAXEL hebdomadaire et de la GEMCITABINE à faible dose chez des patients atteints d'un cancer du pancréas

Adenocarcinoma Metastatic 1 2 3 or more Chemotherapy

Systemic Treatment-Naive

3 recruiting sites

1Globe Health Institute LLC

Phase 3 Pancreas cancer #NCT00268411

[GEMOX] GEMCITABINE et OXALIPLATINE dans le traitement des patients atteints d'un cancer métastatique du pancréas

Adenocarcinoma Metastatic None Systemic Treatment-Naive

Chemotherapy Radiotherapy Chemotherapy Radiotherapy

14 recruiting sites

GERCOR - Groupe Coopératif Multidisciplinaire d'Oncologie

Phase 3 Kidney cancer Pancreas cancer Liver and bile duct cancer Stomach and esophageal cancer #NCT04498767

[OligoRARE] Radiothérapie corporelle stéréotaxique chez les patients atteints de cancers oligométastatiques rares

Metastatic

Systemic Treatment-Naive

2 recruiting sites

EORTC - Organisation Européenne pour la Recherche et le Traitement du Cancer

Phase 2 / Phase 3 Prostate cancer Colon cancer Rectal cancer Anal cancer Pancreas cancer Stomach and esophageal cancer Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT06943755 #2025-521043-20-00

Zanzalintinib versus évérolimus chez les participants atteints de tumeurs neuroendocrines localement avancées ou métastatiques

Neuroendocrine tumor Locally Advanced Metastatic Metastatic Castration-resistant 1 2 3 or more

Systemic Treatment-Naive

1 recruiting site

Exélixis